angelMD has announced their platform’s first investment. Seattle based Kineta was the beneficiary of angelMD’s investment, terms were not disclosed.
Kineta, founded in 2008 by experienced entrepreneurs Drs. Charles Magness and Shawn Iadonato, has a five compound pipeline with their lead drug being ShK-186 in Phase 1B clinical trial for psoriatic arthritis. Kineta is also the major subcontractor of a University of Washington project which was awarded an NIH grant of up to $11.6 million to develop novel vaccine adjuvants, agents that help boost the body’s immune response.
“Kineta has a solid management team, great science, and an innovative funding strategy that creates opportunity for our physician investors. They are a great match for the angelMD physician community and we’re excited about watching and participating in their success,” said Charles Weaver, MD, angelMD SVP of Clinical and Business Development.
Charles Magness Kineta CEO added,
“angelMD delivers the same creative approach to healthcare funding that Kineta brings to biotechnology development. Their model is perfectly aligned with the interests of innovative companies, and we are excited to have a network of clinicians partnering with us financially.”
Based in San Francisco and Seattle, angelMD is a private equity firm leveraging a powerful crowdfunding platform that connects physician investors with innovative medical startups seeking capital investments, advisors, and users.
Sponsored Links by DQ Promote
Reg A - Form 1-A Filings Beta
Beta. Initial Form 1-A only. Target raise is the stated Amount to be Raised, totaled. Compared with the same dates one year earlier.
YTD: Jan 1, 2026 - Oct 22, 2026 vs Jan 1, 2025 - Oct 22, 2025
Share this graph
Number of Filings131Prior 125 +4.8%
Target Raise, Total$3.40BPrior $3.54B -3.9%
This YTD
Year prior
Change
Filings
131
125
+4.8%
Target raise
$3.40B
$3.54B
-3.9%
Sponsored by
the Crowded Media Group
the leading digital news service covering the global Fintech Industry, including digital assets, crowdfunding, tokenization, and other innovations in capital markets. email us@CrowdfundInside
This display counts initial Form 1-A filings only. It does not represent subsequent filings, including Form 1-A/A amendments or Form 1-A POS post-qualification updates filed by the issuer. Amounts are the stated Amount to be Raised on the initial filing, not capital raised and not amounts revised in later filings.
Crowdfund Insider is the leading news website covering the emerging global industry of disruptive finance including investment crowdfunding, Blockchain, online lending, and other forms of Fintech.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it and agree to our terms of service.
“Kineta has a solid management team, great science, and an innovative funding strategy that creates opportunity for our physician investors. They are a great match for the angelMD physician community and we’re excited about watching and participating in their success,” said Charles Weaver, MD, angelMD SVP of Clinical and Business Development.
